Antidepressant discontinuation syndrome in clinical and laboratory studies - Implications for clinicians and patients;Zespół objawów odstawiennych po lekach antydepresyjnych w badaniach naukowych - Implikacje dla lekarzy i pacjentów

Psychiatria Polska

Volumn 43, Issue 5, 2009, Pages 545-555

  Heitzman, Janusz ^a,b   Solak, Magdalena ^c  

^a Klinika Psychiatrii Sa̧dowej ^*  (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

Antidepressant drugs; Clinical sudies; Discontinuation syndrome

Indexed keywords

ANTIDEPRESSANT AGENT; NORADRENALIN; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ANTIDEPRESSANT DISCONTINUATION SYNDROME; ARTICLE; CHOLINERGIC SYSTEM; CLINICAL FEATURE; HUMAN; LABORATORY TEST; NEUROLOGIC DISEASE; DEPRESSION; DOSE RESPONSE; DRUG EFFECT; METABOLISM; PATIENT COMPLIANCE; REVIEW; SYNDROME; TREATMENT REFUSAL; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PATIENT COMPLIANCE; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME; SYNDROME; TREATMENT REFUSAL;

EID: 77950480802     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Lejoyeux M, Ades J, Mourad I i in. Antidepressant withdrawal syndrome: recognition, prevention, and management. CNS Drugs 1996; 4: 278-292.
2. Fava M. Prospective studies of adverse events related to antidepressant discontinuation. J. Clin. Psychiatry 2006; 67: 14-21.
3. Dilsaver SC, Greden JF. Antidepressant withdrawal phenomena. Biol. Psychiatry 1984; 19: 237-256.
4. Therrien F, Markowitz JS. Selective serotonin reuptake inhibitors and withdrawal symptoms: a review of the literature. Hum. Psychopharmacol. 1997; 12: 309-323.
5. Haddad P. Newer antidepressants and the discontinuation syndrome. J. Clin. Psychiatry 1997; 58 (supl. 7): 17-21.
6. Fava M, Mulroy R, Alpert J i in. Emergence of adverse events following discontinuation of treatment with extendedrelease venlafaxine. Am J. Psychiatry 1997; 154: 1760-1762.
7. Rosenbaum JF, Fava M, Hoog SL i in. Selective serotonin reuptake inhibitors discontinuation syndrome: a randomized clinical trial. Biol. Psychiatry 1998; 44: 77-87.
8. Kellner R. A symptom questionare. J. Clin. Psychiatry 1987; 48: 268-274.
9. Hamilton M. A rating scale for depression. J. Neurosurg. Psychiatry 1960; 23: 56-62.
10. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Brit. J. Psychiatry 1979; 134: 382-389.
11. Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int. Clin. Psychopharmacol. 2000; 15: 305-318.
12. Judge R, Parry MG, Quail D i in. Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int. Clin. Psychopharmacol. 2002; 17: 217-225.
13. Bogetto F, Bellino S, Revello RB i in. Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS Drugs 2002; 16: 273-283.
14. Montgomery SA, Huuson AK, Bothmer J. A randomized study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychol. 2004; 50: 57-64.
15. Delgado PL. Depression: the case for a monoamine deficiency. J. Clin. Psychiatry 2000; 61: 7-11.
16. Delgado PL, Miller HL, Salomon RM i in. Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol. Psychiatry 1999; 46: 212-220.
17. Sjoerdsma A, Engelman K, Spector S i in. Inhibition of catecholamine synthesis in man with alpha-methyl-tyrosine, an inhibitor of tyrosine hydroxylase. Lancet 1965; 286: 1092-1094.
18. Young SN, Smith SE, Phil RO i in. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacol. 1985; 87: 173-177.
19. Delgado PL, Moreno FA, Onate L i in. Sequential catecholamine and serotonin depletion in mirtazapine-treated patients. Int. J. Neuropsychopharmacol. 2002; 5: 63-66.
20. Curzon G. Relationship between plasma, CSF and brain tryptophan. J. Neural Transm. 1979 (supl.); 15: 81-92.
21. Curzon G. Influence of plasma tryptophan brain 5 HT synthesis and serotonergic activity. Adv. Exp. Med. Biol. 1981; 133: 207-219.
22. Moreno FA, McGavin C i in. Tryptophan depletion selectively reduces CSF 5HT metabolite in healthy young men: results from single lumbar puncture sampling technique. Int. J. Neuropsychopharmacol. 2000; 3: 277-283.
23. Smith KA, Fairburn CG, Cowen PJ. Relapse of depression after rapid depletion of tryptophan. Lancet 1997; 349: 915-919.
24. Leyton M, Young SN, Blier P i in. The effect of tryptophan depletion on mood in medication-free, former patients with major affective disorder. Neuropsychopharmacol. 1997; 16: 294-297.
25. Moreno FA, Heninger GRi in. Tryptophan depletion and risk of depression relapse: a prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol. Psychiatry 2000; 48: 327-329.
26. Miller HL, Delgado PL, Salomon RM i in. Effects of alfa-metyl-para-tyrosine (AMPT) in drug-free depressed patients. Neuropsychopharmacol. 1996; 14: 151-157.
27. Delgado PL, Charney DS i in. Serotonin function and the mechanizm of antidepressant action reversal of antidepressants-induced remission by rapid depletion of plasma tryptophan. Arch. Gen. Psychiatry 1990; 47: 411-418.
28. Delgado PL, Miller HL i in. Monoamines and the mechanism of antidepressant action, effects of catecholamine depletion on mood of patients treated with antidepressants. Psychopharmacol. Bull. 1993; 29: 389-396.
29. O'Reardon JP, Chopra MP i in. Response to tryptophan depletion in major depression treated with either cognitive therapy or selective serotonin reuptake inhibitor antidepressants. Biol. Psychiatry 2004; 55: 957-959.
30. Neumeister A, Praschak-Rieder N i in. Rapid tryptophan depletion in drug-free depressed patients with seasonal affective disorder. Am. J. Psychiatry 1997; 154: 1153-1155.
31. Neumeister A, Praschak-Rieder N i in. Effects of tryptophan depletion on drug-free patients with seasonal affective disorder during stable response to bright light therapy. Arch. Gen. Psychiatry 1997; 54: 133-138.
32. Neumeister A, Praschak-Rieder N i in. Effects of tryptophan depletion in fully remitted patients with seasonal affective disorder during summer. Psychol. Med. 1998; 28: 257-264.
33. Moja EA, Cipolla P i in. Dose-response decrease in plasma tryptophan and in brain tryptophan and serotonin after tryptophan-free amino acid mixtures in rats. Life Sc. 1989; 44: 971-976.
34. Young SN, Ervin FR, Phil RO i in. Biochemical aspects of tryptophan depletion in primates. Psychopharmacol. 1989; 98: 508-511.
35. Carpenter LL, Anderson GM i in. Tryptophan depletion turing continuous CSF sampling in health human subjects. Neuropsychopharmacol. 1998; 19: 26-35.
36. Williams WA, Shoaf SE i in. Effects of acute tryptophan depletion on plasma and cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in normal volunteers. J. Neurochem. 1999; 72 : 1641-1647.
37. Delgado PL, Charney DS i in. Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects. Life Sc. 1989; 45: 2323-2332.
38. Barr LC, Goodman WK i in. Tryptophan depletion inpatients with obsessive-compulsive disorder who respond to serotonin reuptake inhibitors. Arch. Gen. Psychiatry 1994; 51: 309-317.
39. Smeraldi E, Diaferia G i in. Tryptophan depletion in obsessive-compulsive patients. Biol. Psychiatry 1996; 40: 398-402.
40. Coccaro EF. Central serotonin and impulsive aggression. Brit. J. Psychiatry 1989 (supl.); 8: 52-62.
41. Delgado PL. Monoamine depletion studies: implications for antidepressant discontinuation syndrome. J. Clin. Psychiatry 2006; 67 (supl. 4): 22-26.